>
Switch to:

Orgenesis Inventories, Finished Goods

: $0.00 Mil (As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

Orgenesis Inventories, Finished Goods Historical Data

The historical data trend for Orgenesis's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Inventories, Finished Goods
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Inventories, Finished Goods Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Orgenesis Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:CASI ROCO:6461 NAS:PRTG XKRX:291650 NAS:ENTX TSE:4588 OSTO:ACE NAS:EYEN TSX:ONC XKRX:072520
Traded in Other Exchanges
45O:Germany 45O:Germany
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Website
https://www.orgenesis.com
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

From GuruFocus

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair

By Marketwired 06-10-2021

Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies

By Don Li2 11-15-2021

Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs

By GuruFocusNews 11-29-2021

Orgenesis to Present Today at the Winter Wonderland Conference-Best Ideas from the Buy-Side

By Marketwired 02-16-2021

Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts

By Marketwired 08-20-2020

Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

By GuruFocusNews 01-27-2022

Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders

By Marketwired 11-03-2020

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

By Marketwired 06-01-2021

Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related Transaction

By Marketwired 10-19-2020

Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform

By Marketwired 11-05-2020

Other Sources

$ORGS - Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing. Orgenesis A Mispriced Biotech Visionary

By Seekingalpha 2021-05-17

$ORGS - Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile. Orgenesis Cell And Gene Therapy Disruptor Nice Risk Reward Profile

By Seekingalpha 2021-01-28

$ORGS - Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-11-06

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)